AMP.L

Amphion Innovations Plc
Amphion Innovations - Loan facility update
12th June 2019, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8862B
Amphion Innovations PLC
12 June 2019
 

AMPHION INNOVATIONS PLC

 ("Amphion" or "the Company")

  

Loan facility update

 

12 June 2019, London and New York - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces an update in respect of its loan facility.

 

The Company has been notified by the Company's debt provider (the "Lender") that, further to the terms of the loan facility which were announced on 11 March 2019 and 1 April 2019 (the "Facility"), the excess value of the collateral above the loan balance does not presently meet the terms of the Facility. As of 11 June 2019, the loan balance outstanding pursuant to the Facility is approximately US $3.2 million (including fees and accrued interest) and the number of Motif shares held was 10,900,591.  The Board is working closely with the Lender regarding potential resolution in connection with the collateral requirement and further announcements will be made as appropriate. 

 

The Company remains highly cash constrained and continues to consider both its short term and medium term funding options and work with the Company's note holders. The outstanding Facility balance plus accrued interest are currently due for repayment on 30 September 2019. 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

For further information please contact:

 

Amphion Innovations

Tel: +1 (212) 210 6224

Charlie Morgan




Panmure Gordon Limited (Nominated Adviser and Corporate Broker)

Tel: +44 (0)20 7886 2500

Emma Earl/ Freddy Crossley  (Corporate Finance)


Charles Leigh-Pemberton (Corporate Broking)




SP Angel Corporate Finance LLP (Joint Corporate Broker)

Tel: +44 (0) 20 3470 0470

David Hignell (Corporate Finance)


Vadim Alexandre (Corporate Broking)




Walbrook PR

Tel: +44 (0)20 7933 8780 or amphion@walbrookpr.com

Anna Dunphy / Paul McManus


 

 

 

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.

 

On the web: www.amphionplc.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEANKFFALNEFF ]]>
TwitterFacebookLinkedIn